Skip to main content Back to Top


Cyclosporine Oral Solution

Products Affected - Description

    • Cyclosporine oral solution, Teva, 100 mg/mL, 50 mL bottle, NDC 00591-2224-55
    • Cyclosporine oral solution, Teva, 100 mg/mL, 50 mL bottle, NDC 00172-7313-20

Reason for the Shortage

    • Teva has cyclosporine oral solution on shortage due to an active pharmaceutical ingredient delay.

Available Products

    • Sandimmune oral solution, Novartis, 100 mg/mL, 50 mL bottle, NDC 00078-0110-22
    • Gengraf oral solution, AbbVie, 100 mg/mL, 50 mL bottle, NDC 00074-7269-50
    • Neoral oral solution, Novartis, 100 mg/mL, 50 mL bottle, NDC 00078-0274-22

Estimated Resupply Dates

    • Teva has cyclosporine modified oral solution on back order and the company estimates a release date of late-June 2020.


Updated November 26, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 24, 2019 by Rachael Freeman, PharmD, BCPS. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins